In yesterday’s Wall Street session, Johnson & Johnson (NYSE:JNJ) shares traded at $158.38, up 2.41% from the previous session.
23 analysts cover Johnson & Johnson (NYSE:JNJ), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $215.00 and a low of $155.00, we find $172.00. Given the previous closing price of $154.66, this indicates a potential upside of 11.21 percent. JNJ stock price is now 3.52% away from the 50-day moving average and -0.64% away from the 200-day moving average. The market capitalization of the company currently stands at $381.27B.
The stock has received a hold rating from 13 analysts and a buy rating from 8. Brokers who have rated the stock have averaged $175.42 as their price target over the next twelve months.
With the price target enhanced from $167 to $180, UBS Upgraded its rating from Neutral to Buy for Johnson & Johnson (NYSE: JNJ).
In other news, Hait William, insider sold 14,698 shares of the company’s stock on Jul 26. The stock was sold for $2,528,056 at an average price of $172.00. Upon completion of the transaction, the insider now directly owns 87,747 shares in the company, valued at $13.9 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 25, Exec VP, Chief HR Officer Fasolo Peter sold 20,000 shares of the business’s stock. A total of $3,406,498 was realized by selling the stock at an average price of $170.32. This leaves the insider owning 102,696 shares of the company worth $16.26 million. Insiders disposed of 619,105 shares of company stock worth roughly $98.05 million over the past 1 year. A total of 0.17% of the company’s stock is owned by insiders.
On Friday morning Johnson & Johnson (NYSE: JNJ) stock kicked off with the opening price of $156.44. During the past 12 months, Johnson & Johnson has had a low of $144.95 and a high of $181.04. As of last week, the company has a debt-to-equity ratio of 0.42, a current ratio of 1.21, and a quick ratio of 0.96. According to the stock market information, the enterprise value for the company is $387.67B, which is based on a 30.23 price-to-earnings ratio, a 5.81 price-to-earnings-growth ratio, and a beta of 0.57. The fifty day moving average price for JNJ is $152.93 and a two-hundred day moving average price translates $159.39 for the stock.
The latest earnings results from Johnson & Johnson (NYSE: JNJ) was released for Sep, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $2.66, beating analysts’ expectations of $2.52 by 0.14. This compares to $0.06 EPS in the same period last year. The net profit margin was 14.31% and return on equity was 17.70% for JNJ. The company reported revenue of $21.35 billion for the quarter, compared to $20.0 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.78 percent. For the current quarter, analysts expect JNJ to generate $20.99B in revenue.
Johnson & Johnson(JNJ) Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company’s Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
